封面
市場調查報告書
商品編碼
1624062

脫髮症市場規模、佔有率和成長分析(按疾病類型、治療方法、性別、銷售管道、最終用途和地區):行業預測(2025-2032)

Alopecia Market Size, Share, Growth Analysis, By Disease type (Alopecia Areata, Cicatricial), By Treatment (Pharmaceuticals, Devices), By Gender, By Sales Channel, By End Use, By Region - Industry Forecast 2025-2032

出版日期: | 出版商: SkyQuest | 英文 165 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

2023年全球脫髮症市場規模預計為87.1億美元,預測期內(2025-2032年)複合年成長率為8.0%,從2024年的94.1億美元增至2032年的17.4億美元。 1000萬美元。

由於消費者對功效更高、副作用最小的先進毛髮修復藥物的需求不斷增加,脫髮症治療市場正在顯著成長。細胞激素療法和再生細胞療法等著名的新治療方法因其透過促進細胞特化和控制毛髮生長週期來促進毛髮生長的能力而越來越受歡迎。此外,聯合治療已被證明有效,目前受到消費者的青睞。市場預計將出現創新解決方案,包括多功能成分和促進毛髮生長的先進療法,例如幹細胞療法和低強度雷射療法。市場規模預計將從2024年的94.5億美元擴大到2032年的181.8億美元,預計脫髮症領域將在雷射帽和頭盔等創新產品的推動下強勁擴張。

目錄

介紹

  • 分析目的
  • 市場範圍
  • 定義

分析方法

  • 資訊採購
  • 次要/主要資料方法
  • 市場規模預測
  • 市場假設與約束

執行摘要

  • 市場概況及展望
  • 供需趨勢分析
  • 按細分市場的機會分析

市場動態及展望

  • 市場概況
  • 市場規模
  • 市場動態
    • 促進因素和機遇
    • 限制因素和挑戰
  • 波特分析

主要市場考慮因素

  • 關鍵成功因素
  • 競爭程度
  • 主要投資機會
  • 市場生態系統
  • 市場魅力指數(2024)
  • PESTEL分析
  • 總體經濟指標
  • 價值鏈分析
  • 價格分析
  • 技術分析
  • 監管分析
  • 專利分析
  • 案例研究

全球脫髮症市場規模/複合年成長率:按疾病類型分類(2025-2032)

  • 市場概況
  • 脫髮症
  • 疤痕的
  • 牽引功率
  • 雄性脫毛症

全球脫髮症市場規模/複合年成長率:依治療方法分類(2025-2032)

  • 市場概況
  • 藥品
  • 醫療設備

全球脫髮症市場規模/複合年成長率:性別(2025-2032)

  • 市場概況
  • 男性
  • 女士

全球脫髮症市場規模/複合年成長率:依銷售管道分類(2025-2032)

  • 市場概況
  • 處方箋
  • OTC

全球脫髮症市場規模/複合年成長率:依最終用途分類(2025-2032)

  • 市場概況
  • 居家醫療
  • 皮膚科診所

全球脫髮症市場規模/複合年成長率(2025-2032)

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 西班牙
    • 法國
    • 英國
    • 義大利
    • 其他歐洲國家地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地區
  • 中東/非洲
    • 海灣合作理事會國家
    • 南非
    • 其他中東/非洲

競爭格局

  • 前5名企業對比
  • 主要企業市場定位(2024年)
  • 主要企業採取的策略
  • 近期市場趨勢
  • 主要企業市場佔有率(2024年)
  • 主要企業簡介
    • 公司簡介
    • 產品系列分析
    • 按細分市場分類的佔有率分析
    • 收益與前一年同期比較(2022-2024)

主要企業簡介

  • Johnson & Johnson
  • Merck & Co.
  • Pfizer Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • Aclaris Therapeutics, Inc.
  • Concert Pharmaceuticals, Inc.
  • HCell Inc.
  • Follica, Inc.
  • Histogen Inc.
  • Allergan plc
  • Bayer AG
  • Kythera Biopharmaceuticals, Inc.
  • Polichem SA
  • Takeda Pharmaceutical Company Limited
  • Almirall, SA
  • Perrigo Company plc
  • Vegalab, Inc.

結論和建議

簡介目錄
Product Code: SQSG35I2021

Global Alopecia Market size was valued at USD 8.71 billion in 2023 and is poised to grow from USD 9.41 billion in 2024 to USD 17.41 billion by 2032, growing at a CAGR of 8.0% during the forecast period (2025-2032).

The alopecia treatment market is experiencing significant growth driven by increased consumer demand for advanced hair-restoration medications with improved efficacy and minimal side effects. Notable emerging therapies, such as cytokine therapy and regenerative cell therapy, are gaining traction for their ability to enhance hair regrowth by promoting cellular specialization and regulating the hair growth cycle. Additionally, combination therapies have proven effective and are currently the preferred choice among consumers. The market is expected to see innovative solutions, including multifunctional ingredients and advanced treatments like stem cell therapy and low-level laser therapy, which are enhancing hair regrowth. With a projected market size increase from USD 9.45 Billion in 2024 to USD 18.18 Billion by 2032, the alopecia sector is set for robust expansion, marked by innovative products like laser caps and helmets.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Alopecia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Alopecia Market Segmental Analysis

Global Alopecia Market is segmented by Disease type, Treatment, Gender, Sales Channel, End Use and region. Based on Disease type, the market is segmented into Alopecia Areata, Cicatricial, Traction and Androgenetic Alopecia. Based on Treatment, the market is segmented into Pharmaceuticals and Devices. Based on Gender, the market is segmented into Male and Female. Based on Sales Channel, the market is segmented into Prescriptions and OTC. Based on End Use, the market is segmented into Homecare setting and Dermatology clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Alopecia Market

The global alopecia market is poised for expansion, driven by the increasing prevalence of hair loss conditions. The American Academy of Dermatology Association (AAD) reported that in 2021, approximately 30 million women and 50 million men in the U.S. were affected by alopecia. Notably, around 60% of individuals experience some degree of hair thinning, with pattern hair loss being the most widespread form among both sexes, according to the Journal of Clinical and Diagnostic Research (JCDR). Furthermore, research indicates that 2% of the general population will experience alopecia areata in their lifetime. The rising costs associated with healthcare are propelling the alopecia market forward, particularly due to initiatives from organizations like the American Hair Loss Association and the National Alopecia Areata Foundation, which focus on educating the public about treatment options and hair regrowth strategies. Alopecia areata, like many autoimmune disorders, may have hereditary factors and unknown triggers linked to hair loss. Conditions such as multiple sclerosis, type 1 diabetes, and other autoimmune diseases have shown connections to increased risks for alopecia, further emphasizing the need for awareness and treatment. As public and private campaigns continue to promote awareness and education on alopecia, coupled with the growing statistics on autoimmune diseases and lifestyle factors, the global alopecia market will likely see substantial growth in the coming years.

Restraints in the Global Alopecia Market

The growth of the global alopecia market faces several challenges that may hinder its expansion. One significant restraint is the high cost associated with treatments, which can deter potential consumers. Additionally, in emerging countries, the market will confront obstacles due to inadequate primary care services and insufficient healthcare infrastructure. Furthermore, from 2022 to 2028, stringent regulatory frameworks and low public awareness regarding alopecia and its treatments will further constrain market growth. These factors combined create a challenging environment that could impede the overall advancement of the alopecia market in the coming years.

Market Trends of the Global Alopecia Market

The Global Alopecia market is poised for significant growth, driven by rising incidences of chronic conditions such as arthritis, PCOS, and cancer, along with lifestyle changes and heightened stress levels among populations. The increasing prevalence of hormonal imbalances and unhealthy dietary habits has further fueled demand for effective alopecia treatments, including medications and surgical procedures like hair transplantation. Additionally, an aging population emphasizes the need for targeted solutions in this sector. With substantial market potential in emerging regions, innovative treatment options are expected to shape growth trends, offering lucrative opportunities for stakeholders in the forthcoming years.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Technology Analysis
  • Regulatory Analysis
  • Patent Analysis
  • Case Studies

Global Alopecia Market Size by Disease type & CAGR (2025-2032)

  • Market Overview
  • Alopecia Areata
  • Cicatricial
  • Traction
  • Androgenetic Alopecia

Global Alopecia Market Size by Treatment & CAGR (2025-2032)

  • Market Overview
  • Pharmaceuticals
  • Devices

Global Alopecia Market Size by Gender & CAGR (2025-2032)

  • Market Overview
  • Male
  • Female

Global Alopecia Market Size by Sales Channel & CAGR (2025-2032)

  • Market Overview
  • Prescriptions
  • OTC

Global Alopecia Market Size by End Use & CAGR (2025-2032)

  • Market Overview
  • Homecare setting
  • Dermatology clinics

Global Alopecia Market Size & CAGR (2025-2032)

  • North America (Disease type, Treatment, Gender, Sales Channel, End Use)
    • US
    • Canada
  • Europe (Disease type, Treatment, Gender, Sales Channel, End Use)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Disease type, Treatment, Gender, Sales Channel, End Use)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Disease type, Treatment, Gender, Sales Channel, End Use)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Disease type, Treatment, Gender, Sales Channel, End Use)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Johnson & Johnson
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Cipla Limited
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Dr. Reddy's Laboratories Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sun Pharmaceutical Industries Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline plc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Aclaris Therapeutics, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Concert Pharmaceuticals, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • HCell Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Follica, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Histogen Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Allergan plc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Kythera Biopharmaceuticals, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Polichem S.A.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company Limited
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Almirall, S.A.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Perrigo Company plc
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Vegalab, Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations